Drugs Made In America Acquisition II (NASDAQ:DMII) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Drugs Made In America Acquisition II (NASDAQ:DMII) to a hold rating in a report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings raised Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a research note on Tuesday, September 1st. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Drugs Made In America Acquisition II currently has an average rating of “Sell”.

Drugs Made In America Acquisition II Price Performance

Shares of Drugs Made In America Acquisition II stock opened at $10.19 on Friday. The firm’s fifty day simple moving average is $10.17 and its 200-day simple moving average is $10.07. Drugs Made In America Acquisition II has a 12 month low of $9.86 and a 12 month high of $10.33.

Drugs Made In America Acquisition II (NASDAQ:DMII) last issued its quarterly earnings results on Friday, August 14th. The company reported $0.07 earnings per share for the quarter.

Institutional Investors Weigh In On Drugs Made In America Acquisition II

A number of institutional investors have recently bought and sold shares of DMII. Gabelli Funds LLC acquired a new position in Drugs Made In America Acquisition II during the 1st quarter worth $1,609,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Drugs Made In America Acquisition II during the first quarter worth $1,790,000. Sona Asset Management US LLC boosted its holdings in Drugs Made In America Acquisition II by 66.7% in the first quarter. Sona Asset Management US LLC now owns 500,000 shares of the company’s stock worth $4,985,000 after purchasing an additional 200,000 shares during the period. SkyView Investment Advisors LLC acquired a new position in Drugs Made In America Acquisition II in the second quarter worth $2,515,000. Finally, Rivernorth Capital Management LLC bought a new stake in Drugs Made In America Acquisition II during the first quarter valued at $2,991,000.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ: DMII) is a special purpose acquisition company (SPAC). The company was established to pursue a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Its stated focus is on identifying a target in the pharmaceutical, biotechnology or related healthcare sectors, with an emphasis on companies involved in drug development, manufacturing or other activities connected with medicines produced in the United States.